Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Conditions
Keywords
HNSCC, Metastatic, Recurrent, Elderly, Geriatry
Brief summary
The aim of the trial is to evaluate the clinical benefit (efficacy, safety, preservation of autonomy) of cetuximab-carboplatin-5FU combination as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma in patients over 70 years without frailty (after geriatric assessment).
Interventions
DRUGCarbo, 5FU, Cetuximab
6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w) Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity
Sponsors
Gustave Roussy, Cancer Campus, Grand Paris
Groupe Oncologie Radiotherapie Tete et Cou
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age greater than or equal to 70 years * patient enrolled in ELAN-ONVOCAL study and evaluated as fit (harmonious aging) by GERICO screening method for geriatric frailty * life expectancy superior to 12 weeks * creatinin clearance \> ou equal to 50ml/mn calculated using Modification of Diet in Renal Disease (MDRD) formula * hematologic function : absolute neutrophil count \> 1.5 x 10\^9/l, platelets \> 100 x 10\^9/l, hemoglobin \> 9,5 g/dl * liver function : total bilirubin inferior to 1,25 x Upper limit of normal (ULN), SGOT/SGPT inferior to 5 x ULN, PAL inferior to 5 x ULN * PS \< 2 The disease: * histologically proven head and neck squamous cell carcinomas * recurrent or metastatic. Visceral metastases or locoregional recurrence unsuitable for curative locoregional treatment: unsuitable for primitive tumor surgery due to local extension (evidently authorized for lymph nodes) and unsuitable for radiotherapy for primitive tumor (or already performed) due to metastatic dissemination and the absence of indication for re-irradiation of primitive tumor. * Presence of at least one measurable lesion (defined by RECIST criteria) by CT scan or IRM * asymptomatic cerebral metastases authorized General: * signed Informed Consent Form * affiliated to the French social security system (or a beneficiary of this system) according to the provisions of the law of 9 August 2004
Exclusion criteria
* Previous systemic chemotherapy, except for chemotherapy as part of multimodal treatment for locally advanced cancer completed more than 6 months prior to study enrollment * Known contraindication specific to one of study treatments (particularly cardiac for 5FU) * Known dihydropyrimidine dehydrogenase deficiency (DPD deficiency). * Patients considered as unfit (fragile) by GERICO screening method for geriatric frailty * Irradiation within 4 weeks prior to study enrollment. * Nasopharyngeal, rhinopharyngeal or maxillary sinus carcinoma. * Presence of infection (infection requiring intravenous antibiotics), including tuberculosis and HIV infection (human immunodeficiency virus). * Concomitant treatment with other antitumor immunotherapy or hormonal therapy. * Other antitumor concomitant therapies. * Prior treatment with EGFR-targeted therapy (epidermal growth factor receptor). * Treatment with one of study drugs within 30 days prior to study enrollment. * Presence of documented symptomatic brain or leptomeningeal metastases * Clinically significant coronaropathy or antecedent myocardial infarction within 12 months prior to study enrollment or high-risk uncontrolled arrhythmias or uncontrolled heart failure. * Medically uncontrolled arterial hypertension * Other prior or concomitant cancer, with exception for carcinoma in situ of the uterine cervix, or for cutaneous basal cell carcinoma within 5 years prior to study enrollment. * Presence of medical or physiological factors susceptible to modify patient compliance with study protocol and follow-up or Informed Consent Form signing. * Known allergy or hypersensibility to monoclonal antibodies (bevacizumab, cetuximab), or to other chemotherapies of the study or to their excipients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response and acute toxicity | 1 month after the end of chemotherapy | Objective tumor response at 12 weeks, safety (no grade 3, 4, 5 toxicities) and preservation of geriatric autonomy (absence of 2 or more points decrease on the Activities of Daily Living (ADL) scale) 1 month after the end of chemotherapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 1 year after the end of treatment | Overall survival |
| progression free survival | 1 year after the end of treatment | progression free survival |
| Duration of response under cetuximab maintenance therapy | 1 year after the end of maintenance | Duration of response under cetuximab maintenance therapy |
| Best objective tumor response | 6 weeks after the end of treatment | Best objective tumor response during treatment |
| autonomy | 1 month after the end of treatment | Autonomy assessed by ADL and IADL scales during treatment and until 1 month after the end of treatment |
| Health related quality of life | 1 month after the end of chemotherapy | Quality of life assessed by EORTC QLQ-C30 and QLQ-HN35 questionnaires |
| Toxicity of cetuximab maintenance therapy | 3 months after the end of maintenance | Toxicity of cetuximab maintenance therapy |
Countries
France
Outcome results
None listed